These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 36640618)

  • 1. Inhibiting the inhibitors: Development of the IAP inhibitor xevinapant for the treatment of locally advanced squamous cell carcinoma of the head and neck.
    Ferris RL; Harrington K; Schoenfeld JD; Tahara M; Esdar C; Salmio S; Schroeder A; Bourhis J
    Cancer Treat Rev; 2023 Feb; 113():102492. PubMed ID: 36640618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Xevinapant or placebo plus chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck: TrilynX phase III study design.
    Bourhis J; Burtness B; Licitra LF; Nutting C; Schoenfeld JD; Omar M; Bouisset F; Nauwelaerts H; Urfer Y; Zanna C; Cohen EE
    Future Oncol; 2022 May; 18(14):1669-1678. PubMed ID: 35172587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Xevinapant plus radiotherapy in resected, high-risk, cisplatin-ineligible LA SCCHN: the phase III XRay Vision study design.
    Ferris RL; Mehanna H; Schoenfeld JD; Tahara M; Yom SS; Haddad R; König A; Witzler P; Bajars M; Tourneau CL
    Future Oncol; 2024 Apr; 20(12):739-748. PubMed ID: 38197296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trial.
    Tao Y; Sun XS; Pointreau Y; Le Tourneau C; Sire C; Kaminsky MC; Coutte A; Alfonsi M; Calderon B; Boisselier P; Martin L; Miroir J; Ramee JF; Delord JP; Clatot F; Rolland F; Villa J; Magne N; Elicin O; Gherga E; Nguyen F; Lafond C; Bera G; Calugaru V; Geoffrois L; Chauffert B; Damstrup L; Crompton P; Ennaji A; Gollmer K; Nauwelaerts H; Bourhis J
    Eur J Cancer; 2023 Apr; 183():24-37. PubMed ID: 36796234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evasion of apoptosis and treatment resistance in squamous cell carcinoma of the head and neck.
    O'Leary B; Skinner H; Schoenfeld JD; Licitra L; Le Tourneau C; Esdar C; Schroeder A; Salmio S; Psyrri A
    Cancer Treat Rev; 2024 Sep; 129():102773. PubMed ID: 38878677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term results from a clinical study of xevinapant plus chemoradiotherapy in people with high-risk locally advanced squamous cell carcinoma of the head and neck: a plain language summary.
    Tao Y; Sun XS; Pointreau Y; Tourneau CL; Sire C; Gollmer K; Crompton P; Bourhis J
    Future Oncol; 2023 Aug; 19(26):1769-1776. PubMed ID: 37439181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Effect of Xevinapant Combined with Ionizing Radiation on HNSCC and Normal Tissue Cells and the Impact of Xevinapant on Its Targeted Proteins cIAP1 and XIAP.
    Fleischmann J; Hildebrand LS; Kuhlmann L; Fietkau R; Distel LV
    Cells; 2023 Jun; 12(12):. PubMed ID: 37371123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Model-Informed Selection of the Recommended Phase III Dose of the Inhibitor of Apoptosis Protein Inhibitor, Xevinapant, in Combination with Cisplatin and Concurrent Radiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck.
    Vugmeyster Y; Ravula A; Rouits E; Diderichsen PM; Kleijn HJ; Koenig A; Wang X; Schroeder A; Goteti K; Venkatakrishnan K
    Clin Pharmacol Ther; 2024 Jan; 115(1):52-61. PubMed ID: 37777832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Managing cisplatin-ineligible patients with resected, high-risk, locally advanced squamous cell carcinoma of the head and neck: Is there a standard of care?
    Haddad RI; Harrington K; Tahara M; Szturz P; Le Tourneau C; Salmio S; Bajars M; Lee NY
    Cancer Treat Rev; 2023 Sep; 119():102585. PubMed ID: 37392723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel approach of prophylactic radiation to reduce toxicities comparing 2-step40 with 56-Gy simultaneous integrated boost intensity-modulated radiation therapy for locally advanced squamous cell carcinoma of the head and neck, an intergroup phase III trial (JCOG1912, NEW BRIDGE).
    Yokota T; Zenda S; Kodaira T; Kiyota N; Fujimoto Y; Wasano K; Takahashi R; Mizowaki T; Homma A; Sasaki K; Machida R; Sekino Y; Fukuda H; ;
    BMC Cancer; 2023 Nov; 23(1):1068. PubMed ID: 37932681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The expanding role of IAP antagonists for the treatment of head and neck cancer.
    Kansal V; Kinney BLC; Uppada S; Saba NF; Stokes WA; Buchwald ZS; Schmitt NC
    Cancer Med; 2023 Jul; 12(13):13958-13965. PubMed ID: 37132167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial.
    Burtness B; Bourhis JP; Vermorken JB; Harrington KJ; Cohen EE
    Trials; 2014 Nov; 15():469. PubMed ID: 25432788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
    Lee NY; Ferris RL; Psyrri A; Haddad RI; Tahara M; Bourhis J; Harrington K; Chang PM; Lin JC; Razaq MA; Teixeira MM; Lövey J; Chamois J; Rueda A; Hu C; Dunn LA; Dvorkin MV; De Beukelaer S; Pavlov D; Thurm H; Cohen E
    Lancet Oncol; 2021 Apr; 22(4):450-462. PubMed ID: 33794205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I study of cabazitaxel in combination with platinum and 5-fluorouracil (PF) in locally advanced squamous cell carcinoma of head and neck (LA-SCCHN).
    Camille N; Rozehnal J; Roy E; Uczkowski D; Olson A; Genden E; Teng M; Bakst R; Gupta V; Posner M; Misiukiewicz K
    Oral Oncol; 2017 Aug; 71():99-104. PubMed ID: 28688700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Highlights of the ASCO and ESMO annual meetings 2022: radiotherapy of head and neck cancer].
    Schnellhardt S; Linxweiler M; Gostian AO; Hecht M
    HNO; 2023 Jul; 71(7):446-452. PubMed ID: 37296331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck.
    Del Campo JM; Hitt R; Sebastian P; Carracedo C; Lokanatha D; Bourhis J; Temam S; Cupissol D; De Raucourt D; Maroudias N; Nutting CM; Compton N; Midwinter D; Downie L; Biswas-Baldwin N; El-Hariry I; Harrington KJ
    Br J Cancer; 2011 Aug; 105(5):618-27. PubMed ID: 21829197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gemcitabine-Based Chemoradiation in the Treatment of Locally Advanced Head and Neck Cancer: Systematic Review of Literature and Meta-Analysis.
    Vanderveken OM; Szturz P; Specenier P; Merlano MC; Benasso M; Van Gestel D; Wouters K; Van Laer C; Van den Weyngaert D; Peeters M; Vermorken J
    Oncologist; 2016 Jan; 21(1):59-71. PubMed ID: 26712958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy in recurrent and or metastatic squamous cell carcinoma of the head and neck.
    Saada-Bouzid E; Peyrade F; Guigay J
    Curr Opin Oncol; 2019 May; 31(3):146-151. PubMed ID: 30893146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicenter phase II trial of paclitaxel, carboplatin, and cetuximab followed by chemoradiotherapy in patients with unresectable locally advanced squamous cell carcinoma of the head and neck.
    Enokida T; Ogawa T; Homma A; Okami K; Minami S; Nakanome A; Shimizu Y; Maki D; Ueda Y; Fujisawa T; Motegi A; Ohkoshi A; Taguchi J; Ebisumoto K; Nomura S; Okano S; Tahara M
    Cancer Med; 2020 Mar; 9(5):1671-1682. PubMed ID: 31943834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.
    Caponigro F; Di Gennaro E; Ionna F; Longo F; Aversa C; Pavone E; Maglione MG; Di Marzo M; Muto P; Cavalcanti E; Petrillo A; Sandomenico F; Maiolino P; D'Aniello R; Botti G; De Cecio R; Losito NS; Scala S; Trotta A; Zotti AI; Bruzzese F; Daponte A; Calogero E; Montano M; Pontone M; De Feo G; Perri F; Budillon A
    BMC Cancer; 2016 Nov; 16(1):918. PubMed ID: 27884140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.